(Q44472091)

English

Paradigm of combination biologics: analytical challenges related to pharmacokinetic assays and interpretation of pharmacokinetic and immunogenicity results

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Paradigm of combination biologics: analytical challenges related to pharmacokinetic assays and interpretation of pharmacokinetic and immunogenicity results (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Lauren Stevenson

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Kimberly Zinnack

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jean Donley

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lisa Beebe

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lakshmi Amaravadi

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

487-498

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Key elements of bioanalytical method validation for macromolecules

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Bioanalytical method validation for macromolecules in support of pharmacokinetic studies

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Clinical pharmacokinetics of therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Drug interactions evaluation: an integrated part of risk assessment of therapeutics

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies

1 reference

https://api.crossref.org/works/10.4155%2FBIO.10.214

21 January 2018

Identifiers

10.4155/BIO.10.214

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44472091&oldid=2143363599"